You are here: Industry Insights > Market News > Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Dry powder Inhaler(DPI)

Pressurized Metered Dose Inhaler(pMDI)

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

expresspharmaJanuary 28, 2021

Tag: Nordic Capital , Advanz , Cidron

Favorites

PE investor Nordic Capital has offered to buy Advanz Pharma, valuing the company at $846 million as part of a move to invest in accelerating the company’s pipeline of innovative specialty pharma products.

Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share and can also elect a non-cash alternative offer to receive unlisted shares in Cidron Aida for each Advanz Pharma share.

Previous:Unichem gets USFDA approval for Zonisamide Capsules

Next:Lilly, Vir and GSK collaborate for trial of Covid-19 therapies

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>